Contents of this document
Earnings presentation materialsSecond quarter of the fiscal year ended December 20256 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥24,554 million+4.0%
Operating profit¥1,637 million
Ordinary income¥1,173 million
Net income-559 Millions of yen net loss attributable to owners of the parent
Full-year earnings forecast
Net Sales
¥50,000 million
Adjusted EBITDA
¥6,200 million
Operating profit
¥2,400 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales51%
Adjusted EBITDA70%
Operating profit136%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
利益は計画を大幅に上回るペースで拡大Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
Euglena Healthcare+¥200 million
エポラMEJ-¥160 million
Q'SAI+¥360 million
Satis Pharma+18.7億円
Other Healthcare-15.4億円
Biofuels+¥150 million
Adjusted EBITDA
M&A impact+¥165 million
Gross profit+¥418 million
Advertising expenses+¥138 million
Other selling expenses+478百万円
Personnel Expenses+¥22 million
Administrative expenses+¥131 million
Research and Development Expenses+¥57 million
Subsidy Income-¥23 million
Operating profit
Adjusted EBITDA3,508百万円
Grant income (non-operating)-¥27 million
減価償却費（M&A以外）-306百万円
減価償却費（M&A関連）-877百万円
Goodwill amortization-477百万円
株式関連報酬-185百万円
New initiatives
- マレーシアのバイオ燃料商業プラント運営会社への15%出資
- 微細藻類入り肥料・飼料ブランド『いきものたちにユーグレナ』の本格始動
- ファインケミカルを加えた『新バイオマスの5F』を基本戦略化
- 精製パラミロンの開発
- 大規模培養タンクによるスケールアップ実証
Key KPIsA metric the company considers important as a management benchmark.
ヘルスケア調整後EBITDAマージン
Value
- FY2023 H1 11.5%
- FY2023 H2 10.6%
- FY2024 H1 14.8%
- FY2024 H2 14.9%
- FY2025 H1 19.5%
Segment results
Net Sales
Euglena Healthcare+2.0億円（CONCが急成長）
エポラMEJ-1.6億円（C COFFEEの投資抑制）
Q'SAI+3.6億円（コラリッチ好調）
Satis Pharma+18.7億円（前年同期から連結寄与、受注も拡大）
Other Healthcare-15.4億円（前年同期に子会社売却）
Biofuels+1.5億円（原料取引・国内販売が拡大）
Adjusted EBITDA
Euglena Healthcare+¥541 million
エポラMEJ+¥38 million
Q'SAI+278百万円
Satis Pharma+¥135 million
Other Healthcare-¥129 million
Biofuels+¥90 million
Other-¥1 million
Corporate Expenses-?（図中表示あり、金額判読不能）
Medium-term management plan targets
Transition to a profitable business model前期に達成済み
FY2025黒字定着・拡大
| Item | Details |
|---|---|
| Document type | Earnings presentation materials |
| Fiscal Period Covered | Second quarter of the fiscal year ended December 2025 |
| Net Sales | ¥24,554 million (YoY +4.0%) |
| Operating profit | ¥1,637 million |
| Ordinary income | ¥1,173 million |
| Net income | -559 Millions of yen (net loss attributable to owners of the parent) |
| Full-year earnings forecast | Net Sales ¥50,000 million / Adjusted EBITDA ¥6,200 million / Operating profit ¥2,400 million |
| Progress against full-year forecast | Net Sales 51% / Adjusted EBITDA 70% / Operating profit 136% |
| Self-assessment against the plan | 利益は計画を大幅に上回るペースで拡大 |
| Segment results | Net Sales Euglena Healthcare +2.0億円（CONCが急成長） / エポラMEJ -1.6億円（C COFFEEの投資抑制） / Q'SAI +3.6億円（コラリッチ好調） / Satis Pharma +18.7億円（前年同期から連結寄与、受注も拡大） / Other Healthcare -15.4億円（前年同期に子会社売却） / Biofuels +1.5億円（原料取引・国内販売が拡大） / Adjusted EBITDA Euglena Healthcare +¥541 million / エポラMEJ +¥38 million / Q'SAI +278百万円 / Satis Pharma +¥135 million / Other Healthcare -¥129 million / Biofuels +¥90 million / Other -¥1 million / Corporate Expenses -?（図中表示あり、金額判読不能） |
| Breakdown of Factors Affecting the Change | Net Sales Euglena Healthcare +¥200 million / エポラMEJ -¥160 million / Q'SAI +¥360 million / Satis Pharma +18.7億円 / Other Healthcare -15.4億円 / Biofuels +¥150 million / Adjusted EBITDA M&A impact +¥165 million / Gross profit +¥418 million / Advertising expenses +¥138 million / Other selling expenses +478百万円 / Personnel Expenses +¥22 million / Administrative expenses +¥131 million / Research and Development Expenses +¥57 million / Subsidy Income -¥23 million / Operating profit Adjusted EBITDA 3,508百万円 / Grant income (non-operating) -¥27 million / 減価償却費（M&A以外） -306百万円 / 減価償却費（M&A関連） -877百万円 / Goodwill amortization -477百万円 / 株式関連報酬 -185百万円 |
| Key KPIs | ヘルスケア調整後EBITDAマージン value FY2023 H1 11.5%, FY2023 H2 10.6%, FY2024 H1 14.8%, FY2024 H2 14.9%, FY2025 H1 19.5% / yoy_pct Not disclosed |
| Medium-term management plan targets | Transition to a profitable business model 前期に達成済み / FY2025 黒字定着・拡大 |
| New initiatives | マレーシアのバイオ燃料商業プラント運営会社への15%出資, 微細藻類入り肥料・飼料ブランド『いきものたちにユーグレナ』の本格始動, ファインケミカルを加えた『新バイオマスの5F』を基本戦略化, 精製パラミロンの開発, 大規模培養タンクによるスケールアップ実証 |
Items this document does not state (17)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesThree months of the current quarterUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.